- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Winter 2019
| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Pfizer Inc. v. Sun Pharm. Indus. Ltd., 18-1529 (D. Del.) | Oct. 3, 2018 | Hon. Leonard P. Stark | Xeljanz XR® (tofacitinib extended-release tablets) | 9,937,181 |
| Spectrum Pharms., Inc. v. Fresenius Kabi USA, LLC, 18-1533 (D. Del.) | Oct. 3, 2018 | Hon. Colm F. Connolly | Beleodaq® (belinostat for injection) | 6888027 8835501 |
| Bayer Healthcare LLC v. Apotex Inc., 18-1539 (D. Del.) | Oct. 4, 2018 | Hon. Leonard P. Stark | Nexavar® (sorafenib tosylate tablets) | 8877933 9737488 |
| Pharmacyclics LLC v. Sun Pharma Global FZE, 18-1543 (D. Del.) | Oct. 5, 2018 | Hon. Colm F. Connolly | Imbruvica® (ibrutinib capsules) | 10,004,746 |
| Patheon Softgels Inc. v. PuraCap Pharm. LLC, 18-14693 (D.N.J.) | Oct. 5, 2018 | Hon. Michael A. Shipp | Naproxen Sodium (EQ 200 mg Base) OTC capsules | 9,693,978 9,693,979 10,022,344 10,028,925 |
| Celgene Corp. v. Breckenridge Pharm., Inc., 18-14715 (D.N.J.) | Oct. 5, 2018 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 9,993,467 |
| Sun Pharma Global FZE v. Teva Pharm. Indus. Ltd., 18-1552 (D. Del.) | Oct. 9, 2018 | Hon. Richard G. Andrews | Yonsa® (abiraterone acetate tablets) | 9,889,144 |
| Sumitomo Dainippon Pharma Co., Ltd. v. Alkem Labs. Ltd., 18-14787 (D.N.J.) | Oct. 9, 2018 | Hon. Stanley R. Chesler | Latuda® (lurasidone HCl tablets)) | 9815827 9907794 |
| AstraZeneca AB v. Mylan Pharms. Inc., 18-1562 (D. Del.) | Oct. 11, 2018 | Hon. Colm F. Connolly | Symbicort® (budesonide / formoterol fumarate dehydrate inhalation aerosol) | 7,759,328 8,143,239 8,575,137 7,967,011 |
| Shionogi Inc. v. Amneal Pharms. LLC, 18-1564 (D. Del.) | Oct. 11, 2018 | Hon. Mitchell S. Goldberg | Fortamet® (metformin HCl extended-release tablets) | 6790459 6866866 |
| Par Pharm., Inc. v. Sandoz Inc., 18-14895 (D.N.J.) | Oct. 11, 2018 | Hon. Brian R. Martinotti | Vasostrict® (vasopressin injection) | 9,375,478 9,687,526 9,744,209 9,744,239 9,750,785 9,937,223 |
| AstraZeneca AB v. Mylan Pharms. Inc., 18-0193 (N.D.W.V.) | Oct. 12, 2018 | Hon. Irene M. Keeley | Symbicort® (budesonide / formoterol fumarate dehydrate inhalation aerosol) | 7,759,328 8,143,239 8,575,137 7,967,011 |
| Teva Pharms. Int’l GMBH v. Fresenius Kabi USA, LLC, 18-1586 (D. Del.) | Oct. 15, 2018 | Hon. Colm F. Connolly | Bendeka® (bendamustine HCl for injection) | 10010533 10052385 |
| Galderma Labs., L.P. v. Sun Pharm. Indus. Ltd., 18-1588 (D. Del.) | Oct. 15, 2018 | Hon. Leonard P. Stark | Oracea® (doxycycline capsules) | 10,058,564 |
| Anacor Pharms., Inc. v. Lupin Ltd., 18-1606 | Oct. 17, 2018 | Hon. Leonard P. Stark | Kerydin® (tavaborole topical solution) | 9,459,938 9,566,289 9,566,290 9,572,823 |
| Valeant Pharms. North America LLC v. Taro Pharms. U.S.A., Inc., 18-15060 (D.N.J.) | Oct. 17, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 7,214,506 8,039,494 8,486,978 9,302,009 9,566,272 9,662,394 9,861,698 9,877,955 |
| Millennium Pharms., Inc. v. Hetero Labs Ltd., 18-1639 (D. Del.) | Oct. 22, 2018 | Hon. Colm F. Connolly | Velcade® (bortezomib for injection) | 6713446 6958319 |
| Mylan Specialty L.P. v. Aurobindo Pharma USA Inc., 18-15190 (D.N.J.) | Oct. 22, 2018 | Hon. Freda L. Wolfson | AccuNeb® (albuterol sulfate inhaler) | 6,702,997 |
| Apotex Inc. v. Gilead Sciences, Inc., 18-6475 (N.D. Cal.) | Oct. 23, 2018 | Hon. Joseph C. Spero | Lexiscan® (regadenoson for injection) | 8106183 9085601 |
| Anacor Pharms., Inc. v. Ascent Pharms., Inc., 18-1673 (D. Del.) | Oct. 25, 2018 | Hon. Richard G. Andrews | Kerydin® (tavaborole topical solution) | 9,459,938 9,566,289 9,566,290 9,572,823 |
| Helsinn Healthcare S.A. v. Baxter Healthcare Corp., 18-1674 (D. Del.) | Oct. 25, 2018 | Hon. Richard G. Andrews | Aloxi® (palonosetron HCl for injection) | 8598219 8729094 |
| Astellas US LLC v. Apotex Inc., 18-1675 (D. Del.) | Oct. 25, 2018 | Hon. Colm F. Connolly | Lexiscan® (regadenoson for injection) | 8106183 9085601 |
| Astellas US LLC v. Sandoz Inc., 18-1676 (D. Del.) | Oct. 25, 2018 | Hon. Colm F. Connolly | Lexiscan® (regadenoson for injection) | 8106183 9085601 |
| Astellas US LLC v. Sun Pharma Global FZE, 18-1677 (D. Del.) | Oct. 25, 2018 | Hon. Colm F. Connolly | Lexiscan® (regadenoson for injection) | 8106183 9085601 |
| Astellas US LLC v. Wockhardt Bio AG, 18-1678 (D. Del.) | Oct. 25, 2018 | Hon. Colm F. Connolly | Lexiscan® (regadenoson for injection) | 8106183 9085601 |
| Adapt Pharma Operations Ltd. v. Perrigo UK Finco Ltd. Partnership, 18-15287 (D.N.J.) | Oct. 25, 2018 | Hon. Jose L. Linares | Narcan® (naloxone HCl nasal spray) | 9,211,253 9,468,747 9,561,177 9,629,965 9,775,838 |
| AstraZeneca AB v. Teva Pharms. USA, Inc., 18-1685 (D. Del.) | Oct. 26, 2018 | Hon. Colm F. Connolly | Symbicort® (budesonide / formoterol fumarate dehydrate inhalation aerosol) | 7,759,328 8,143,239 8,575,137 7,967,011 |
| Boehringer Ingelheim Pharms. Inc. v. Mankind Pharma Ltd., 18-1689 (D. Del.) | Oct. 26, 2018 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) | 8551957 9949998 |
| Boehringer Ingelheim Pharms. Inc. v. Lupin Ltd., 18-1690 (D. Del.) | Oct. 26, 2018 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) | 8551957 9949998 |
| Anacor Pharms., Inc. v. Mylan Pharms. Inc., 18-1699 (D. Del.) | Oct. 29, 2018 | Hon. Richard G. Andrews | Kerydin® (tavaborole topical solution) | 9,459,938 9,566,289 9,566,290 9,572,823 |
| Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2019-00122 (PTAB) | Oct. 29, 2018 | N/A | Lantus® SoloStar® (insulin glargine recombinant for injection) Apidra® SoloStar® (insulin glulisine recombinant for injection) Toujeo® (Insulin glargine recombinant subcutaneous solution) Soliqua® (insulin glargine / lixisenatide subcutaneous solution) Admelog® Solostar® (insulin lispro for injection) |
8,992,486 |
| Sucampo AG v. Sun Pharm. Indus., Ltd., 18-15482 (D.N.J.) | Oct. 30, 2018 | Hon. Freda L. Wolfson | Amitiza® (lubiprostone capsules) | 7,795,312 8,097,653 8,389,542 8,026,393 8,338,639 8,779,187 8,748,481 |
| Anacor Pharms., Inc. v. Mylan Pharms. Inc., 18-0202 (N.D.W.V.) | Oct. 30, 2018 | Hon. Irene M. Keeley | Kerydin® (tavaborole topical solution) | 9,459,938 9,566,289 9,566,290 9,572,823 |
| Neptune Generics, LLC v. Aventis Pharma S.A., IPR2019-00136 (PTAB) | Oct. 31, 2018 | N/A | Jevtana® Kit (cabazitaxel for injection) | 5,847,170 |
| Boehringer Ingelheim Pharms. Inc. v. Alkem Labs. Ltd., 18-1738 (D. Del.) | Nov. 2, 2018 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) Glyxambi® (empagliflozin / linagliptin tablets) |
8,551,957 9,949,998 7,713,938 |
| Gilead Sciences, Inc. v. Laurus Labs Ltd., 18-1748 (D. Del.) | Nov. 6, 2018 | Hon. Richard G. Andrews | Truvada® (emtricitabine / tenofovir disoproxil fumarate tablets) | 6,642,245 6,703,396 8,592,397 8,716,264 9,457,036 9,744,181 |
| Amneal Pharms. LLC v. Almirall, LLC, IPR2019-00207 (PTAB) | Nov. 6, 2018 | N/A | Aczone® (dapsone topical gel) | 9,517,219 |
| Boehringer Ingelheim Pharms. Inc. v. Aurobindo Pharma Ltd., 18-1757 (D. Del.) | Nov. 7, 2018 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) Glyxambi® (empagliflozin / linagliptin tablets) Synjardy® (empagliflozin / metformin tablets) Synjardy® XR (empagliflozin / metformin extended-release tablets) |
8,551,957 9,949,998 7,713,938 |
| Boehringer Ingelheim Pharms. Inc. v. Laurus Labs Ltd., 18-1758 (D. Del.) | Nov. 7, 2018 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) | 7579449 9949998 |
| Boehringer Ingelheim Pharms. Inc. v. Alembic Pharms. Ltd., 18-1762 (D. Del.) | Nov. 8, 2018 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) Glyxambi® (empagliflozin / linagliptin tablets) Synjardy® (empagliflozin / metformin tablets) |
9949998 7713938 |
| Boehringer Ingelheim Pharms. Inc. v. Zydus Pharms. (USA) Inc., 18-1763 (D. Del.) | Nov. 8, 2018 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) Synjardy® (empagliflozin / metformin tablets) |
7,579,449 9,949,998 7,713,938 |
| Boehringer Ingelheim Pharms. Inc. v. Macleods Pharms. Ltd., 18-1764 (D. Del.) | Nov. 8, 2018 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) Glyxambi® (empagliflozin / linagliptin tablets) Synjardy® (empagliflozin / metformin tablets) |
8,551,957 9,949,998 7,713,938 |
| Boehringer Ingelheim Pharms. Inc. v. Sun Pharm. Indus. Ltd., 18-1765 (D. Del.) | Nov. 8, 2018 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) Glyxambi® (empagliflozin / linagliptin tablets) |
8551957 9949998 |
| Insys Therapeutics, Inc. v. Teva Pharms. USA, Inc. 18-1775 (D. Del.) | Nov. 9, 2018 | Hon. Colm F. Connolly | Subsys® (fentanyl sublingual spray) | 10,016,403 |
| Kythera Biopharmaceuticals, Inc. v. Slayback Pharma LLC, 18-16012 (D.N.J.) | Nov. 9, 2018 | Hon. Brian R. Martinotti | Kybella® (deoxycholic acid injection) | 8,101,593 8,367,649 8,653,058 |
| Celgene Corp. v. Mylan Pharms. Inc., 18-16035 (D.N.J.) | Nov. 9, 2018 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 9,993,467 |
| Pharmacyclics LLC v. Hetero USA Inc., 18-1778 (D. Del.) | Nov. 12, 2018 | Hon. Colm F. Connolly | Imbruvica® (ibrutinib capsules) | 8,754,090 9,296,753 9,540,382 9,713,617 9,725,455 |
| Boehringer Ingelheim Pharms. Inc. v. Dr. Reddy’s Labs., Ltd., 18-1779 (D. Del.) | Nov. 12, 2018 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) | 9949998 7713938 |
| Dr. Reddy’s Labs., Inc. v. AstraZeneca AB, 18-16057 (D.N.J.) | Nov. 12, 2018 | Hon. Renee Marie Bumb | Nexium® 24HR (esomeprazole magnesium delayed-release oral tablets) | 6,428,810 |
| Boehringer Ingelheim Pharms. Inc. v. Aizant Drug Research Solutions PRV. Ltd., 18-1783 (D. Del.) | Nov. 13, 2018 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) | 8551957 9949998 |
| Boehringer Ingelheim Pharms. Inc. v. MSN Labs. Private Ltd., 18-1785 (D. Del.) | Nov. 13, 2018 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) Glyxambi® (empagliflozin / linagliptin tablets) Synjardy® XR (empagliflozin / metformin extended-release tablets) |
8551957 9949998 |
| Boehringer Ingelheim Pharms. Inc. v. Annora Pharma Private Ltd., 18-1786 (D. Del.) | Nov. 13, 2018 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) Glyxambi® (empagliflozin / linagliptin tablets) |
8,551,957 9,949,997 9,949,998 |
| Boehringer Ingelheim Pharms. Inc. v. Prinston Pharm. Inc., 18-1787 (D. Del.) | Nov. 13, 2018 | Hon. Colm F. Connolly | Glyxambi® (empagliflozin / linagliptin tablets) | 8551957 9949998 |
| Boehringer Ingelheim Pharms. Inc. v. Invagen Pharms., Inc., 18-1788 (D. Del.) | Nov. 13, 2018 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) | 9,949,998 |
| Boehringer Ingelheim Pharms. Inc. v. Cipla Ltd., 18-1789 (D. Del.) | Nov. 13, 2018 | Hon. Colm F. Connolly | Synjardy® XR (empagliflozin / metformin extended-release tablets) | 9,949,998 |
| Dr. Reddy’s Labs. S.A. v. Indivior UK Ltd., IPR2019-00328 (PTAB) | Nov. 13, 2018 | N/A | Suboxone® (buprenorphine HCl / naloxone HCl film) | 9,687,454 |
| Dr. Reddy’s Labs. S.A. v. Indivior UK Ltd., IPR2019-00329 (PTAB) | Nov. 13, 2018 | N/A | Suboxone® (buprenorphine HCl / naloxone HCl film) | 9,687,454 |
| Genzyme Corp. v. Apotex Inc., 18-1795 (D. Del.) | Nov. 14, 2018 | Hon. Colm F. Connolly | Cerdelga® (eliglustat capsules) | 7,196,205 |
| Genzyme Corp. v. Teva Pharms. USA, Inc., 18-1796 (D. Del.) | Nov. 14, 2018 | Hon. Colm F. Connolly | Cerdelga® (eliglustat capsules) | 6,916,802 7,196,205 7,253,185 7,615,573 |
| Medicure Int’l, Inc. v. Gland Pharma Ltd., 18-16246 (D.N.J.) | Nov. 16, 2018 | Hon. Kevin McNulty | Aggrastat® (tirofiban HCl for injection) | 6,770,660 |
| Astellas Pharma Inc. v. Xellia Pharms. APS, 18-1818 (D. Del.) | Nov. 19, 2018 | Hon. Richard G. Andrews | Mycamine® (micafungin sodium for injection) | 6,774,104 |
| Maia Pharms., Inc. v. Bracco Diagnostics Inc., IPR2019-00345 (PTAB) | Nov. 19, 2018 | N/A | Kinevac® (sincalide for injection) | 6,803,046 |
| Genzyme Corp. v. Aizant Drug Research Solutions Private Ltd., 18-1837 (D. Del.) | Nov. 20, 2018 | Hon. Colm F. Connolly | Cerdelga® (eliglustat capsules) | 7,196,205 |
| Genzyme Corp. v. Cipla Ltd., 18-1838 (D. Del.) | Nov. 20, 2018 | Hon. Colm F. Connolly | Cerdelga® (eliglustat capsules) | 6,916,802 7,196,205 7,253,185 7,615,573 |
| Genzyme Corp. v. Dr. Reddy’s Labs., Inc., 18-1839 (D. Del.) | Nov. 20, 2018 | Hon. Colm F. Connolly | Cerdelga® (eliglustat capsules) | 7,196,205 |
| Genzyme Corp. v. Dr. Reddy’s Labs., Inc., 18-16378 (D.N.J.) | Nov. 21, 2018 | Hon. Brian R. Martinotti | Cerdelga® (eliglustat capsules) | 7,196,205 |
| Celgene Corp. v. Apotex Inc., 18-16395 (D.N.J.) | Nov. 21, 2018 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 9,993,467 |
| AstraZeneca Pharms. LP v. Alkem Labs. Ltd., 18-16399 (D.N.J.) | Nov. 21, 2018 | Hon. Freda L. Wolfson | Daliresp® (roflumilast tablets) | 8,536,206 8,604,064 8,618,142 |
| Leo Pharma A/S v. Perrigo UK Finco Ltd. Partnership, 18-1874 (D. Del.) | Nov. 27, 2018 | Hon. Colm F. Connolly | Finacea® (azelaic acid foam) | 10,117,812 |
| BTG Int’l Ltd. v. Qilu Pharm. Co., Ltd., 18-16521 (D.N.J.) | Nov. 28, 2018 | Hon. Kevin McNulty | Zytiga® (abiraterone acetate tablets) | 8,822,438 |
| Duchesnay Inc. v. Actavis Labs. FL, Inc., 18-1895 (D. Del.) | Nov. 29, 2018 | Hon. Richard G. Andrews | Bonjesta® (doxylamine succinate / pyridoxine HCl extended-release tablets) | 9,089,489 9,375,404 9,526,703 9,937,132 |
| Collegium Pharm., Inc. v. Teva Pharms. USA, Inc., 18-1900 (D. Del.) | Nov. 30, 2018 | Hon. Leonard P. Stark | Xtampza® ER (oxycodone extended-release capsules) | 9968598 10004729 |
| Duchesnay Inc. v. Actavis Labs. FL, Inc., 18-25015 (S.D. Fla.) | Nov. 30, 2018 | Hon. Kathleen M. Williams | Bonjesta® (doxylamine succinate / pyridoxine HCl extended-release tablets) | 9,089,489 9,375,404 9,526,703 9,937,132 |
| Boehringer Ingelheim Pharms., Inc. v. Lupin Atlantis Holdings SA, 18-16708 (D.N.J.) | Nov. 30, 2018 | Hon. Brian R. Martinotti | Spiriva® HandiHaler® (tiotropium bromide inhalation powder) | 6,777,423 6,908,928 7,309,707 7,642,268 |
| Bayer Intellectual Property GmbH v. Teva Pharms. USA, Inc., 18-1926 (D. Del.) | Dec. 5, 2018 | Hon. Richard G. Andrews | Xarelto® (rivaroxaban tablets) | 9,539,218 |
| Genzyme Corp. v. Fresenius Kabi USA, LLC, 18-1934 (D. Del.) | Dec. 6, 2018 | Hon. Kent A. Jordan | Mozobil® (plerixafor for injection) | 7897590 6987102 |
| Pfizer Inc. v. Teva Pharms. USA, Inc., 18-1940 (D. Del.) | Dec. 7, 2018 | Hon. Leonard P. Stark | Xeljanz XR® (tofacitinib extended-release tablets) | 9,937,181 |
| Adapt Pharma Operations Ltd. v. Perrigo UK Finco Ltd. Partnership, 18-16987 (D.N.J.) | Dec. 7, 2018 | Hon. Jose L. Linares | Narcan® (naloxone HCl nasal spray) | 10,085,937 |
| Senju Pharm. Co., Ltd. v. Amneal Pharms. LLC, 18-16991 (D.N.J.) | Dec. 7, 2018 | Hon. Brian R. Martinotti | Prolensa® (bromfenac ophthalmic solution) | 10,085,958 |
| Eagle Pharms., Inc. v. Slayback Pharma LLC, 18-1953 (D. Del.) | Dec. 11, 2018 | Hon. Colm F. Connolly | Balrapzo® (bendamustine HCl for injection) | 9,265,831 9,572,796 9,572,797 10,010,533 |
| Silvergate Pharms., Inc. v. Bionpharma Inc., 18-1962 (D. Del.) | Dec. 12, 2018 | Hon. Leonard P. Stark | Epaned® (enalapril maleate solution) | 9,669,008 9,808,442 10,039,745 |
| Merz Pharms., LLC v. Suven Life Sciences, Ltd., 18-0584 (E.D.N.C.) | Dec. 12, 2018 | Hon. Terrence W. Boyle | Cuvposa® (glycopyrrolate solution) | 7638552 7816396 |
| Keryx Biopharmaceuticals, Inc. v. Lupin Ltd., 18-1968 (D. Del.) | Dec. 13, 2018 | Hon. Leonard P. Stark | Auryxia® (ferric citrate tablets) | 5,753,706 7,767,851 8,093,423 8,299,298 8,338,642 8,609,896 8,754,257 8,754,258 8,846,976 8,901,349 9,050,316 9,328,133 9,757,416 9,387,191 |
| AstraZeneca Pharms. LP v. Chia Tai Tianqing Pharm. Group Co., Ltd., 18-17194 (D.N.J.) | Dec. 13, 2018 | Hon. Renee Marie Bumb | Faslodex® (fulvestrant for injection) | 6,774,122 7,456,160 8,329,680 8,466,139 |
| Apotex Inc. v. UCB Biopharma SPRL, IPR2019-00400 (PTAB) | Dec. 13, 2018 | N/A | Xyzal® Allergy 24HR (levocetirizine dihydrochloride solution) | 8,633,194 |
| Valeant Pharms. North America LLC v. Amneal Pharms. LLC, 18-17246 (D.N.J.) | Dec. 14, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 10,105,444 |
| Vifor Fresenius Medical Care Renal Pharma Ltd. v. Annora Pharma Private Ltd., 18-1996 (D. Del.) | Dec. 17, 2018 | Hon. Leonard P. Stark | Velphoro® (sucroferric oxyhydroxide chewable tablets) | 9,561,251 |
| Abraxis Bioscience, LLC v. HBT Labs, Inc., 18-17304 (D.N.J.) | Dec. 17, 2018 | Hon. John Michael Vazquez | Abraxane® (paclitaxel protein-bound particles for injection) | 7,758,891 7,820,788 7,923,536 8,034,375 8,138,229 8,268,348 8,314,156 8,853,260 9,101,543 9,393,318 9,511,046 9,597,409 |
| Valeant Pharms. Int’l v. Sun Pharm. Indus., Ltd., 18-17312 (D.N.J.) | Dec. 17, 2018 | Hon. Peter G. Sheridan | Uceris® (budesonide tablets) | 10,064,878 |
| AstraZeneca AB v. Apotex Inc., 18-2010 (D. Del.) | Dec. 18, 2018 | Hon. Richard G. Andrews | Movantik® (naloxegol tablets) | 9,012,469 |
| Keryx Biopharmaceuticals, Inc. v. Teva Pharms. USA, Inc., 18-2012 (D. Del.) | Dec. 19, 2018 | Hon. Leonard P. Stark | Auryxia® (ferric citrate tablets) | 7,767,851 8,093,423 8,299,298 8,338,642 8,609,896 8,754,257 8,754,258 8,846,976 8,901,349 9,050,316 9,328,133 9,387,191 9,757,416 |
| Abraxis Bioscience, LLC v. HBT Labs, Inc., 18-2019 (D. Del.) | Dec. 19, 2018 | Hon. Richard G. Andrews | Abraxane® (paclitaxel protein-bound particles for injection) | 7,758,891 7,820,788 7,923,536 8,034,375 8,138,229 8,268,348 8,314,156 8,853,260 9,101,543 9,393,318 9,511,046 9,597,409 |
| Par Pharm., Inc. v. Amphastar Pharms., Inc., 18-2032 (D. Del.) | Dec. 20, 2018 | Hon. Colm F. Connolly | Vasostrict® (vasopressin injection) | 9,375,478 9,687,526 9,744,209 9,744,239 9,750,785 9,937,223 |
| Celgene Corp. v. Hetero Labs Ltd., 18-17463 (D.N.J.) | Dec. 20, 2018 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) | 7,465,800 7,855,217 7,468,363 8,741,929 |
| Valeant Pharms. North America LLC v. Lupin Ltd., 18-17501 (D.N.J.) | Dec. 21, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 10,105,444 |
| Valeant Pharms. North America LLC v. Perrigo Pharma Int’l DAC, 18-17518 (D.N.J.) | Dec. 21, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 10,105,444 |
| Eli Lilly and Co. v. Qilu Pharm. Co., Ltd., 18-17554 (D.N.J.) | Dec. 24, 2018 | Hon. William H. Walls | Cialis® (tadalafil tablets) | 6,943,166 |
| AstraZeneca AB v. MSN Pharms., Inc., 18-2051 (D. Del.) | Dec. 26, 2018 | Hon. Richard G. Andrews | Movantik® (naloxegol tablets) | 9,012,469 |
| Janssen Products, L.P. v. Amneal Pharms. LLC, 18-17585 (D.N.J.) | Dec. 26, 2018 | Hon. William H. Walls | Prezista® (darunavir tablets) | 8,518,987 7,126,015 7,595,408 |
| Biogen Int’l GMBH v. Banner Life Sciences LLC, 18-2054 (D. Del.) | Dec. 27, 2018 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) Bafiertam® (dimethyl fumarate delayed-release capsules) |
7,619,001 |
| Valeant Pharms. North America LLC v. Alkem Labs. Ltd., 18-17731 (D.N.J.) | Dec. 28, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 10,105,444 |
| Valeant Pharms. North America LLC v. Aurobindo Pharma USA Inc., 18-17733 (D.N.J.) | Dec. 28, 2018 | Hon. Peter G. Sheridan | Jublia® (efinaconazole topical solution) | 10,105,444 |
GENERICally Speaking Winter 2019
Related Professionals
Christopher A. Pinahs
Partner
GENERICally Speaking - Vol. 8, No. 4
VIEW FULL NEWSLETTER Related Publications
September 18, 2024
Astellas Pharma, Inc. v. Sandoz Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 9, 2024
Purdue Pharma L.P v. Accord Healthcare Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 4, 2024
Exeltis USA, Inc. v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
August 28, 2024
Teva Branded Pharm. Products R&D, Inc. v. Deva Holding A.S.
GENERICally Speaking Hatch Waxman Bulletin
August 13, 2024
Allergan USA, Inc. v. MSN Labs. Private Ltd.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.